Association between dermatologic adverse events and quality of life in lung cancer patients treated with epidermal growth factor receptor-tyrosine kinase inhibitors

[1] Hsu WH(2018)Overview of current systemic management of EGFR-mutant NSCLC Ann Oncol 29 i3-i9

[2] Yang JC(2017)Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer N Engl J Med 376 629-640

[3] Mok TS(2006)Mechanisms of cutaneous toxicities to EGFR inhibitors Nat Rev Cancer 6 803-812

[4] Loong HH(2016)Skin problems and EGFR-tyrosine kinase inhibitor Jpn J Clin Oncol 46 291-298

[5] Mok TS(2017)Risk of treatment-related toxicities from EGFR tyrosine kinase inhibitors: a meta-analysis of clinical trials of gefitinib, erlotinib, and afatinib in advanced EGFR-mutated non-small cell lung cancer J Thorac Oncol 12 633-643

[6] Wu YL(2018)Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer N Engl J Med 378 113-125

[7] Ahn MJ(2006)Dermatologic side effects associated with the epidermal growth factor receptor inhibitors J Am Acad Dermatol 55 657-670

[8] Garassino MC(2009)Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors Br J Dermatol 161 515-521

[9] Kim HR(2013)Experiences with the FACT-EGFRI-18 instrument in EGFRI-associated mucocutaneous adverse events Support Care Cancer 21 1919-1926

[10] Ramalingam SS(2010)Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life Cancer 116 3916-3923

[1] Hsu WH(2018)Overview of current systemic management of EGFR-mutant NSCLC Ann Oncol 29 i3-i9

[2] Yang JC(2017)Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer N Engl J Med 376 629-640

[3] Mok TS(2006)Mechanisms of cutaneous toxicities to EGFR inhibitors Nat Rev Cancer 6 803-812

[4] Loong HH(2016)Skin problems and EGFR-tyrosine kinase inhibitor Jpn J Clin Oncol 46 291-298

[5] Mok TS(2017)Risk of treatment-related toxicities from EGFR tyrosine kinase inhibitors: a meta-analysis of clinical trials of gefitinib, erlotinib, and afatinib in advanced EGFR-mutated non-small cell lung cancer J Thorac Oncol 12 633-643

[6] Wu YL(2018)Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer N Engl J Med 378 113-125

[7] Ahn MJ(2006)Dermatologic side effects associated with the epidermal growth factor receptor inhibitors J Am Acad Dermatol 55 657-670

[8] Garassino MC(2009)Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors Br J Dermatol 161 515-521

[9] Kim HR(2013)Experiences with the FACT-EGFRI-18 instrument in EGFRI-associated mucocutaneous adverse events Support Care Cancer 21 1919-1926

[10] Ramalingam SS(2010)Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life Cancer 116 3916-3923